tbuckley/cabot-search huggingface dataset:
Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.
Authors: Ralf Trappe, Sylvain Choquet, Stephan Oertel, Veronique LeBlond, Tor Ekman, Monica Sender, Peter Molle, Petra Reinke, Hans Lehmkuhl, Manfred Hummel, Sven Jonas, Ruth Neuhaus, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Daan Dierickx, Ionannis Anagnostopoulos, Martine Raphael, Hanno Riess
Journal: Blood (2007)
Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study
Authors: Qifa Liu, Meiqing Wu, Jing Sun, Yu Zhang, Fen Huang, Hongsheng Zhou, Zhiping Fan, Li Xuan, Guopan Yu, Xutao Guo, Min Dai, Ru Feng
Journal: Blood (2015)
Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.
Authors: A. De Censi, Z. Sun, B. J. K. Thurlimann, C. McIntosh, A. Guerrieri-Gonzaga, A. Monnier, C. Tondini, M. Campone, L. Mauriac, K. Zaman, A. Schoenberger, K. N. Price, R. D. Gelber, A. Goldhirsch, A. S. Coates, S. P. Aebi
Journal: Journal of Clinical Oncology (2011)

516 Background: BIG 1-98 compared adjuvant hormonal therapies in over 8,000 postmenopausal pts with operable, ER-positive breast cancer: 5 years (yrs) of T; 5 yrs of L; sequence of 2 yrs T followed by 3 yrs L (TL); 2 yrs L followed by 3 yrs T (LT). During therapy fractures were more frequent in L (9.8%) and TL (9.4%) compared with T (7.3%) and LT (7.5%); the effect of the regimens on BMD is unknown. Methods: BMD was measured annually by dual energy X-ray absorption in 458 patients enrolled after 3 (n=152), 4 (n=194), and 5 (n=71) yrs from randomization and 1 yr off-treatment. Spine and femur T-scores were analyzed by mixed linear models using time from randomization, treatment allocation, time from randomization by treatment interaction, age, BMI, and prior HRT use as covariates. Results: Pts and tumor characteristics in the substudy did not differ significantly from the main study and among treatment arms. T-score estimates (standard errors) based on the mixed linear model are summarized in the table. BMD in T was superior to the other arms at all time points in spine and femur. Pts on T had better overall BMD than pts on L (overall difference in T-score: Spine=0.42, p=0.06; Femur=0.43, p=0.0007). Pts on LT had better overall BMD than pts always on L (overall difference in T-score: Spine=0.07, p=0.72; Femur=0.22, p=0.06). Notably, in pts on LT, BMD improved with T therapy. One year after treatment completion, the proportion of women with osteoporosis (T-score< 2.5) was 9% on T, 21% on L, 22% on TL and 18% on LT. Conclusions: As expected, adjuvant L therapy causes loss of BMD compared with T in postmenopausal pts. However, the sequence L followed by T appears to preserve BMD while retaining the efficacy of upfront L. Yrs after randomization Treatment arm T L TL LT Spine (L2-4) 3 -0.54 (0.19) -1.09 (0.16) -1.20 (0.16) -1.07 (0.16) 4 -0.69 (0.18) -1.06 (0.15) -1.36 (0.16) -0.98 (0.15) 5 -0.62 (0.18) -1.08 (0.15) -1.36 (0.16) -0.90 (0.15) 6 -0.73 (0.19) -1.00 (0.15) -1.22 (0.16) -0.99 (0.15) Femur 3 -0.86 (0.11) -1.28 (0.09) -1.33 (0.10) -1.20 (0.10) 4 -0.72 (0.11) -1.30 (0.09) -1.44 (0.09) -1.03 (0.08) 5 -0.90 (0.11) -1.29 (0.08) -1.39 (0.09) -0.97 (0.08) 6 -0.89 (0.12) -1.25 (0.08) -1.33 (0.09) -1.05 (0.08)
Uranium and arsenic characterization of well water and sediment in Black Falls, Arizona
Authors: Samuel Salinas, Jani C. Ingram
Journal: Cancer Research (2005)

2193  During the 1940 - 1970’s, uranium mining took place on the Navajo Reservation, resulting in hundreds of abandoned mines and areas of mine waste. Radiation-related health problems resulting from these mining activities have been well documented (Brugge 2002). However, health problems related to the chemical properties of uranium as a heavy metal, along with the presence of arsenic as a co-contaminant, is a concern and under investigation. This study focuses on the seasonal characterization of uranium and arsenic present in water collected from rural wells in the Black Falls area, southeast of Cameron, Arizona. Basic water chemical analyses were performed as well as uranium and arsenic analyses. Field pH measurements were gathered. Anionic characterization of sulfates, bicarbonates, nitrates, and chlorides were collected using Ion Chromatography with a conductivity detector. Cationic analyses consisted of calcium, magnesium, sodium, and potassium. Cationic analyses were determined using Atomic Absorption spectroscopy. Elemental uranium and arsenic analyses were collected by ICP-MS. Sedimentary analysis was gathered by SEM-EDS to further characterize the surrounding soil. Three of the wells were shown to have elevated uranium, arsenic and bicarbonate concentrations. Carbonate complexes are important for speciation studies of uranyl carbonates and arsenates.
Prediction of MHC Class I-Restricted Immunogenic Epitopes of B-Cell Receptors Indicates T Cell-Mediated Immunosurveillance of Malignant B Cell Clones.
Authors: Anna-Maria Strothmeyer, Marcus Duehren-von Minden, Marcelo A Navarrete, Kristina Heining-Mikesch, Hendrik Veelken
Journal: Blood (2009)
Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.
Authors: L. R. Mileshkin, L. S. Rosen, T. Blumenkopf, A. Breazna, S. Darang, J. Davison, J. Gallo, J. W. Goldman, D. D. Wang, S. Zhang, S. G. Eckhardt
Journal: Journal of Clinical Oncology (2011)

e13607^ Background: Abnormalities of the Rho family pathway are involved in different steps of malignant transformation and tumor progression. Of the many effector proteins that bind to active Rho members, P21 activated kinase (PAK) family of serine-threonine kinases, is among the best characterized. PAK consists in 6 isoforms grouped into 2 subgroups: Group 1 (isoforms 1-3) and group 2 (isoforms 4-6). PF309 is a potent ATP-competitive inhibitor of PAK1 and PAK isoforms of group 2. Methods: Adult pts with advanced solid tumors were enrolled in a phase I single agent dose escalation study with a standard 3 + 3 design, with oral PF309 administered daily on a continuous basis. The starting dose of PF309 was 1 mg QD. Tumor response was assessed at baseline and every 8 weeks thereafter. Adverse events (AEs) were recorded according the CTC v3.0. Pharmacokinetic assessment is a study endpoint and pharmacodynamic endpoints are being explored in pre and post-treatment tumor biopsies as well as in surrogate tissue (hair follicles). Results: 20 pts (13 males and 7 females) were treated with PF309 across 6 different dose levels (1 mg QD to 40 mg BID). Median age was 64.5 years and median ECOG PS was 1. The most frequent included tumors were CRC (8 pts), NSCLC (3 pts) and pancreatic cancer (2). Median number of cycles was 3 (range 1 to 10). PF309 was well tolerated. PK data from the last 3 cohorts demonstrated systemic exposure of PF309 that was dose proportional following 10 and 40 mg BID. There were no G3-4 treatment-related AEs or DLTs. Treatment-related AEs were mainly GI: G2 gastroesophageal reflux disease (1 pt), G1 diarrhea (5 pts), G1 nausea and vomiting (3 pts), G1 gastritis and G1 dyspepsia (1 pt each). G1-2 QTcF prolongation was observed in 5 pts, 3 of whom had an abnormal pre-treatment QTcF. No QTcF increase > 60 ms above baseline was observed in any of these patients. G3 lab abnormalities included hyponatremia and bilirubin (1 pt each). So far no tumor responses have been observed but 9 pts have been on study treatment for ≥ 4 cycles. Conclusions: Treatment with PF309 appears to be well tolerated in pts with advanced malignancies. The MTD has not yet been reached. Accrual to this study is ongoing.
A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.
Authors: Jeffrey S. Miller, Claudio G. Brunstein, Sarah Cooley, Michael R. Verneris, Angela Panoskaltsis-Mortari, Linda J. Burns, David McKenna, Kathryn Dusenbery, Cladd Stevens, Pablo Rubensten, Marcie Tomblyn, Mukta Arora, Margaret L. MacMillan, Todd DeFor, Chap Le, Philip B. McGlave, Bruce R. Blazar, Daniel J. Weisdorf
Journal: Blood (2006)
Coronary Artery Bypass Grafting in the Acute Phase After Renal Transplantation:Report of a Case
Authors: Tomoe Katoh, Yoshitaka Ikeda, Hidenori Gohra, Kimikazu Hamano, Yoshihiko Fujimura, Kensuke Esato, Akihiko Aoki, Katsusuke Naito
Journal: Circulation (1999)

To the best of our knowledge, only 3 cases of coronary artery bypass grafting (CABG) performed under cardiopulmonary bypass (CPB) on patients in the chronic phase after renal transplantation have been reported in Japan. The first case of a patient who underwent CABG in the acute phase after renal implantation in Japan is herein described. Perioperatively, oral immunosuppressive agents were discontinued and they were given intravenously. Cyclosporin A (Cy-A) was administered via a continuous intravenous infusion in the acute phase after renal transplantation and closely monitored, because the blood concentration of Cy-A can vary a great deal during the perioperative period. This case report serves to demonstrate that as long as appropriate immunosuppressive drugs are perioperatively administered, CABG under CPB can be safely performed on patients who have undergone renal transplantation without subsequent rejection, infection, or renal damage, even during the acute phase.
Thrombopoietin-Increased DNA-PK-Dependent DNA Repair Limits Hematopoietic STEM and Progenitor CELL Mutagenesis in Response to Irradiation
Authors: Bérengère de Laval, Patrycja Pawlikowska, Benoit Roch, Laurence Petit-Cocault, Chrystele Bilhou-Nabera, Michele Souyri, Murielle Gaudry, Frédéric Pouzoulet, Francoise Porteu
Journal: Blood (2012)
Genome-Wide DNA Methylation Landscape Defines IGHV Mutated and Unmutated B Cell Chronic Lymphocytic Leukemias
Authors: Junfeng Luo, Justin Choi, Lirong Pei, Farrukh Awan, Eun-Joon Lee, Jimei Liu, Austin Shull, Brian A. McCarthy, James M. Wilson, Kristen H. Taylor, Xinguo Wang, Phillip Joe Buckhaults, David H. Munn, Charles W. Caldwell, Xiao-Jie Yan, Nicholas Chiorazzi, Huidong Shi
Journal: Blood (2012)
Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Authors: Andrei R. Shustov, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Yin Yang, Eric L. Sievers, Dana A. Kennedy, Barbara Pro
Journal: Blood (2010)
Copy Number Variation of PROS1 and Protein S Deficiency Are Rare in a Population-Based Case-Control Study On Venous Thrombosis (MEGA study).
Authors: Maria Carolina Pintao, Irene D Bezemer, Andrea Aparecida Garcia, Marieke C.H. de Visser, Carine J.M. Doggen, Pieter H. Reitsma, Frits Rosendaal
Journal: Blood (2009)
Activating Transcription Factor 3 (ATF3) Is Overexpressed in Classical Hodgkin Lymphoma and Is Required for Survival of Hodgkin and Reed-Sternberg Cells in Response to Cellular Stress.
Authors: M. Janz, M. Hummel, M. Truss, B. Wollert-Wulf, S. Mathas, C. Hagemeier, K. Bommert, H. Stein, B. Dorken, R. C. Bargou
Journal: Blood (2004)
BET Bromodomain Degradation As a Therapeutic Strategy in Multiple Myeloma
Authors: Geoffrey M. Matthews, Sara Gandolfi, Johanna Bruggentheis, Ricardo De Matos Simoes, Dennis L Buckley, Yiguo Hu, Michal Sheffer, Hayley Poarch, James E. Bradner, Constantine S Mitsiades
Journal: Blood (2016)
CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia
Authors: Max S Topp, Gerhard Zugmaier, Nicola Goekbuget, Svenja Neumann, Heinz-August Horst, Thorsten Raff, Monika Brueggemann, Michael Kneba, Andreas Viardot, Mathias Schmid, Markus Schaich, Matthias Stelljes, Mariele Goebeler, Heike Pfeiffer, Oliver Ottmann, Thomas Burmeister, Evelyn Degenhard, Margit Schmidt, Jürgen Scheele, Hermann Einsele, Peter Kufer, Matthias Klinger, Dirk Nagorsen, Dieter Hoelzer, Ralf Bargou
Journal: Blood (2010)
A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.
Authors: Muzaffar H. Qazilbash, Rima M. Saliba, Gaurav C. Parikh, Chitra Hosing, Floralyn Mendoza, Donna M. Weber, Michael Wang, Sheeba K. Thomas, Thuy S. Flosser, Partow Kebriaei, Uday Popat, Amin M. Alousi, Marcos de Lima, Richard E. Champlin, Sergio A. Giralt
Journal: Blood (2007)
Interleukin-1β Promotes the Expression of CD34 and Granulocyte Colony-Stimulating Factor-Receptor in Adult Dermal Fibroblasts
Authors: Haruko Tashiro, Ryosuke Shirasaki, Yoko Oka, Tadashi Yamamoto, Nobu Akiyama, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2011)
Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6
Authors: Xiangao Huang, Maurizio Di Liberto, Jamieson Bretz, David Chiron, Peter Martin, Morton Coleman, Jia Ruan, Mitchell R Smith, Scott A Ely, Christopher E. Mason, Phoebe Joy Ho, John P. Leonard, Selina Chen-Kiang
Journal: Blood (2011)
Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Brian T. Hill, Mitchell R. Smith, Jennifer Mears, Amy Healy, Meredeth Shelley, Jeanie Wyckhouse, Janice Kakish, Deepa Jagadeesh, Robert M. Dean, Brad Pohlman, Stephen D. Smith
Journal: Blood (2014)
STUDIES ON VITAL STAINING
Authors: H. P. Smith
Journal: The Journal of Experimental Medicine (1930)

Brilliant vital red injected into the blood stream of dogs is slowly taken up by phagocytes in various parts of the body, but eventually an equilibrium is established, after which the concentration as measured in the plasma remains almost constant for long intervals of time. This equilibrium can be disturbed by injecting more dye, and in this case the phagocytes resume ingestive activity, apparently with normal or nearly normal vigor. This activity continued until a rather large part of the newly injected dye has been removed, and as the reaction again slows up we note that both plasma and tissues contain more dye than before. It is difficult to be certain that the distribution ratio of dye between plasma and tissues remains unaltered with dosage, but evidence indicates that for non toxic doses, at least, this is approximately true. This study of this partition ratio is complicated by the fact that the liver slowly excretes dye into the bile, and this helps to reduce the amount of dye in the body. Partial correction for this factor can be made by ascertaining the dye output in bile fistula dogs. These latter studies show that dye elimination into bile is relatively less efficient when large doses of dye are given to the animal than with smaller dosage. This undue retention of dye in the body with large dosage helps to maintain the dye concentration in the plasma at unduly high levels. These peculiarities in liver excretion have an important bearing on liver physiology in general, and in addition they also have an important application in connection with the theory of "blockade of the reticulo-endothelial system." It is now obvious that prolonged retention of dye in the blood stream does not of itself prove that this group of phagocytic cells is "blocked" against the entrance of foreign material. Altered excretion by liver, kidney, etc. must be ruled out before we can accept such data as evidence of "blockade."
Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy.
Authors: Andrea Lynne Harzstark, Susan Halabi, William Kevin Kelly, Michael J. Morris, Phillip G. Febbo, Eric Jay Small
Journal: Journal of Clinical Oncology (2012)

129 Background: Docetaxel/prednisone (DP) plus bevacizumab (B) demonstrated a superior progression-free survival (PFS) but did not prolong overall survival (OS) in comparison to DP monotherapy in CALGB 90401, a study of 1,050 patients with metastatic castration-resistant prostate cancer (CRPC) who had not received prior chemotherapy for metastatic disease. Tobacco use increases VEGF levels, suggesting the benefit of bevacizumab may be greater in patients who use tobacco. Methods: The association of tobacco usage and OS was evaluated. Patient-reported history of tobacco usage was prospectively collected for patients on CALGB 90401. Within each smoking status group, the log-rank test was used to compare the survival time between the two treatment arms. The proportional hazards model was used to test for smoking by treatment interaction predicting OS. Results: Of 865 patients with available smoking history, 21%, 30% and 49% were current, former, and never smokers. As summarized in the table below, there was a non-statistically significant improvement in OS for current smokers treated on the DP+B arm compared to the DP arm. However, treatment-by-smoking interaction was not statistically significant in predicting OS (p=0.299). Conclusions: There was a trend toward an improvement in OS for current smokers treated with DP+B. The accuracy of patient-reported smoking status will be confirmed with serum cotinine levels in a pilot study. The effect of tobacco use on cancer outcomes with VEGF targeted therapy will be evaluated in other malignancies.
Anti CMV and/or Anti Adenovirus IFN-g-Positive CD4+ CD8+ T Lymphocytes for Treatment of Viral Infections After Allogeneic HSC Transplantation: First Results
Authors: Liliane Dal Cortivo, RITA Creidy, Aurélie Gabrion, Marianne Leruez-Ville, Sebastien Heritier, Fabien Touzot, Guilhem Cros, Sebastien Maury, Alienor Xhaard, Marie Ouachee, Ingrid Hamon, Capucine Picard, Christophe Cambouris, Salima Hacein Bey Abina, Stephane Blanche, Marina Cavazzana-Calvo
Journal: Blood (2012)
Invasive Fungal Infection in Acute Leukemia Patients: What Is Their Impact on the Chemotherapy Schedule?.
Authors: Caroline Even, Cecile Pautas, Yosr Hicheri, Sebastien Maury, Mathieu Kuentz, Francoise Botterel, Stephane Bretagne, Sylvie Bastuji-Garin, Catherine Cordonnier
Journal: Blood (2007)
IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics
Authors: Daniel Mertens, Nupur Bhattacharya, Sarah Häbe, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2012)
An Orally Bioavailable Inhibitor of FLT3 and Syk Kinases Prevents Tumor Growth in Subcutaneously Implanted Human Tumor Xenografts and Promotes Cell Death of FLT3 Mutant AML Cells.
Authors: Polly R. Pine, Rena Bahjat, Betty Chang, Vanessa Taylor, Vadim Markovstov, Yasumichi Hitoshi, Elliott Grossbard
Journal: Blood (2005)
Sex differences in metabolic cardiomyopathy
Authors: Elizabeth Murphy, Georgios Amanakis, Natasha Fillmore, Randi J. Parks, Junhui Sun
Journal: Cardiovascular Research (2017)

In contrast to ischemic cardiomyopathies which are more common in men, women are over-represented in diabetic cardiomyopathies. Diabetes is a risk factor for cardiovascular disease; however, there is a sexual dimorphism in this risk factor: heart disease is five times more common in diabetic women but only two-times more common in diabetic men. Heart failure with preserved ejection fraction, which is associated with metabolic syndrome, is also more prevalent in women. This review will examine potential mechanisms for the sex differences in metabolic cardiomyopathies. Sex differences in metabolism, calcium handling, nitric oxide, and structural proteins will be evaluated. Nitric oxide synthase and PPARα exhibit sex differences and have also been proposed to mediate the development of hypertrophy and heart failure. We focused on a role for these signalling pathways in regulating sex differences in metabolic cardiomyopathies.
Recruitment of the SWI/SNF Chromatin Remodeling Complex by NFATc1 in the Transcriptional Regulation of the C-MYC Oncogene in Aggressive B-Cell Lymphomas
Authors: Lan V. Pham, Archito Tamayo, Hai-Jun Zhou, Yen-Chiu Lin-Lee, Lingchen Fu, Richard J. Ford
Journal: Blood (2008)
Proportions of T-Cell CD8+ Subsets Lacking CD28 Expression at Day 30 after Myeloablative Allogeneic Stem Cell Transplantation Are Predictive for Relapse and Chronic GVHD.
Authors: Ibrahim Yakoub-Agha, Pasquine Saule, Leonardo Magro, Pascale Cracco, Valerie Coiteux, Benedicte Bruno, Manuel Cliquennois, Francoise Dufosse, Jean-Pierre Jouet, Jean-Paul Dessaint, Myriam Labalette
Journal: Blood (2007)
Arousal-biased preferences for sensory input: An agent-centered and multisource perspective
Authors: Kai Kaspar
Journal: Behavioral and Brain Sciences (2016)

I argue that the GANE (glutamate amplifies noradrenergic effects) model basically explains an arousal-based amplification of emotional stimuli, whereas effects on neutral stimuli indicate a contextualization process aiming to reduce stimulus ambiguity. To extend the model's validity, I suggest distinguishing between internal and external emotional sources, as well considering the stimulus valence and addressing age-related differences in attention and memory preferences.
An Novel Approach in Protective Gene Therapy: Recombinant Adeno-Associated Virus 2-Mediated Transfer of the Human Superoxide-Dismutase Gene.
Authors: Marlon R. Veldwijk, Carsten Herskind, Stephanie Laufs, Marius Stiefelhagen, W. Jens Zeller, Stefan Fruehauf, Frederik Wenz
Journal: Blood (2004)
α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI)
Authors: Ekapun Karoopongse, Sabina Janciauskiene, Charles A. Dinarello, H. Joachim Deeg, A. Mario Q. Marcondes
Journal: Blood (2012)
Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.
Authors: Wendy Stock, Jeffrey Johnson, Daohai Yu, Diane Bennett, Dorie Sher, Richard M. Stone, Jonathan E. Kolitz, Bayard L. Powell, Meir Wetzler, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
Journal: Blood (2005)
Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/−) Mouse Bone Marrow as a Model for 5q- MDS
Authors: Arati Khanna-Gupta, Hong Sun, Jian Chen, Stephanie Halene, Paolo Sportoletti, Pier Paolo Pandolfi, Nancy Berliner
Journal: Blood (2008)
Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.
Authors: Mary Lynn Savoie, Alexander Balogh, Ahsan Chaudhry, Douglas A. Stewart, Nizar J. Bahlis, Jan Storek, Christopher Brown, Diana Quinlan, Leanne Kmet, Loree M. Larratt, A. Robert Turner, James A. Russell
Journal: Blood (2006)